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Objective: Chronic pulmonary hypertension is difficult to treat and despite 
the introduction of several therapeutic options, no single therapy is 
universally recommended. Nitric oxide has had some role clinically in 
improving pulmonary hemodynamics in this setting; however, basic inves- 
tigation has not been performed in an appropriate large animal model of 
stable pulmonary hypertension. This study was designed to examine the 
effects of inhaled nitric oxide on pulmonary hemodynamics in the setting of 
a canine model of monocrotaline pyrrole-induced chronic pulmonary 
hypertension and used Fourier analysis for assessment of pulmonary 
vascular impedance. Methods: Sixteen mongrel dogs (22 to 25 kg) were used. 
Animals underwent percutaneous pulmonary artery catheterization to 
measure right-sided hemodynamics before and 6 weeks after a right atrial 
injection of either monocrotaline pyrrole (n = 8) or placebo (n = 8). Six 
weeks after the injection all hearts were instrumented with an ultrasonic 
flow probe, sonomicrometric dimension transducers, and micromanom- 
eters. Data were collected at baseline and after nitric oxide administration. 
Harmonic derivation of functional data was achieved with Fourier analysis. 
Results: Six weeks after the injection, significant increases in pulmonary 
artery pressure and pulmonary vascular esistance were observed in the 
monocrotaline pyrrole group. Nitric oxide led to significant decreases in 
pulmonary vascular impedance. Significant improvements in pulmonary 
blood flow, transpulmonary efficiency, and left ventricular filling were also 
observed. Conclusions: This investigation demonstrates the well-known 
clinical effects of nitric oxide in improving pulmonary hypertension, which 
were also associated with an increase in pulmonary blood flow, transpul- 
monary efficiency, and left ventricular filling in the setting of monocrotaline 
pyrrole-induced pulmonary hypertension. (J Thorac Cardiovasc Surg 1997; 
113:849-57) 
T he clinical management of chronic pulmonary hypertension is challenging and despite the intro- 
duction of several therapeutic measures, no single 
treatment is universally recommended. Numerous 
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pharmacologic agents are used as potential strate- 
gies for improving pulmonary hemodynamics in this 
setting, including prostaglandin El, prostacyclin, 
and sodium nitroprusside. Unfortunately, these 
drugs are not selective for the pulmonary vascular 
bed and, in addition to lowering pulmonary vascular 
pressure, their use is also associated with significant 
decreases in the systemic mean arterial pressure. 1 
Nitric oxide (NO) is a selective pulmonary vaso- 
dilator that has no significant effects on the systemic 
circulation. These hemodynamic properties uggest 
a potentially useful role for NO in improving pul- 
monary hemodynamics in the setting of chronic 
pulmonary hypertension. There are few reports, 
however, that describe the use of NO in reducing 
pulmonary vascular impedance in this clinical sce- 
nario. Furthermore, basic investigation of this prob- 
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lem has been limited by lack of an appropriate 
large-animal model of stable chronic pulmonary 
hypertension. This study was therefore designed to 
examine the effects of inhaled NO on pulmonary 
hemodynamics in the setting of chronic pulmonary 
hypertension, with use of a recently established 
canine model of monocrotal ine pyrrole- induced 
chronic pulmonary hypertension 2 and with Fourier 
analysis for characterization of pulmonary vascular 
impedance and blood flow. 
Material and methods 
Study design, experimental groups, and drug synthesis. 
Sixteen adult mongrel dogs weighing 22 to 25 kg were 
used and divided into two groups. The experimental group 
received an injection of 3 mg/kg of monocrotaline pyrrole 
(MCTP group, n = 8) whereas control animals received 
placebo (CTL group, n = 8). Monocrotaline pyrrole was 
synthesized artificially for use in this study with a well- 
described technique. 3 
Anesthesia, hemodynamic monitoring, and monoero- 
taline pyrrole injection. All animals were anesthetized 
with 5 mg/kg of intravenous thiopental sodium (Gensia 
Laboratories, Irvine, Calif.) and 20 mg/kg of intramuscu- 
lar ketamine sodium (Fort Dodge Laboratories, Fort 
Dodge, Iowa) before all studies, including baseline and 
follow-up hemodynamic measurements, drug injections, 
and NO studies. Each animal also received 900,000 units 
of penicillin G benzathine and penicillin G procaine (Fort 
Dodge Laboratories). All animals were intubated with a 
9F endotracheal tube and the lungs mechanically venti- 
lated with a Bear 1 ventilator (Inter Med, Bear Medical 
Systems, Inc., Riverside, Calif.). The tidal volume was set 
at 15 ml/kg, the fraction of inspired oxygen at 21%, and 
the rate at 10 breaths/rain. Arterial blood samples were 
drawn from the right femoral artery and processed with a 
Gem-Stat blood gas analyzer (Mallinckrodt Sensor Sys- 
tems, Ann Arbor, Mich.). 
All hemodynamic measurements and drug injections 
were done under sterile conditions. For each animal, an 
8.5F introducer sheath (Baxter Healthcare, Irvine, Calif.) 
was placed percutaneously into the external jugular vein 
by the Seldinger technique. A 5F Swan-Ganz catheter 
(Baxter Healthcare) was then advanced through the in- 
troducer sheath into the right atrium, right ventricle, and 
pulmonary artery for measurement of right atrial, right 
ventricular, and pulmonary arterial pressures. All pres- 
sures were monitored with a Horizon 2000 hemodynamic 
monitor (Mennen Medical Inc., Clarence, N.Y.). Hemo- 
dynamic measurements were done at baseline and 6 weeks 
after injection. Monocrotaline pyrrole or placebo was 
injected into the right atrium after measurement of base- 
line pulmonary hemodynamic indices. 
Instrumentation for assessment of cardiopulmonary 
function. At the time of instrumentation, the fraction of 
inspired oxygen was increased to 60% to maintain an 
arterial partial pressure of oxygen of at least 200 to 300 
mm Hg. A standard median sternotomy and an anterior 
pericardiotomy were performed to expose the hearts of all 
animals. An ultrasonic flow probe (T208X, Transonic 
Systems Inc., Ithaca, N.Y.) was placed around the main 
pulmonary trunk to measure pulmonary blood flow. 
Hemispheric ultrasonic dimension transducers (1.5 mm 
outer diameter, No. 1-1015-5A, Vernitron, Bedford, 
Ohio) were positioned across the base-apex major axis, 
anteroposterior minor axis diameter of the left ventricle, 
and septal-free wall minor axis diameters of both the right 
and left ventricles to measure left and right ventricular 
cavitary volumes. Micromanometers (MPC-500, Millar 
Instruments Inc., Houston, Tex.) were placed into the 
right and left ventricle, right and left atrium, and pulmo- 
nary artery for continuous pressure recording of the right 
and left ventricular pressures, right and left atrial pres- 
sures, and pulmonary artery pressure. 
NO administration. NO (NO 777 ppm and NO 2 <0.1 
ppm, National Specialty Gases, Durham, N.C.) was con- 
tinuously blended into the inspiratory circuit of the ven- 
tilator. NO was given in sequential fashion at levels of 40 
and 80 ppm. The NO and nitric dioxide levels of the 
inspired gas were measured by continuous chemilumines- 
cent analysis (model 42H, Thermo Environmental Instru- 
ments, Inc., Franklin, Mass.). 
Experimental protocol during NO studies. Six weeks 
after monocrotaline pyrrole or placebo injection, baseline 
postinjection functional and hemodynamic data were col- 
lected in every animal in both experimental groups after 
instrumentation. CTL-group animals did not undergo any 
further data collection. In the MCTP-group animals, 
inhaled NO was then administered at levels of 40 and 80 
ppm and data were collected at each concentration. After 
each incremental increase in the NO concentration, the 
animal's condition and hemodynamic parameters were 
allowed to equilibrate for 10 minutes before further data 
collection. After data were collected at the dose of 80 
ppm, the NO administration was discontinued and the 
level in the inspiratory circuit of the ventilator was re- 
stored to 0 ppm. Pulmonary hemodynamic parameters 
were then allowed to return to baseline values. 
Data acquisition during baseline and NO studies. All 
data were digitized on-line, collected, and stored on a 
microprocessor (PDP 11/23, Digital Equipment Corp., 
Maynard, Mass.). Pressure data and cardiac output were 
analyzed with software developed in our laboratory that is 
described elsewhere. 4 Briefly, all data were digitized at 
500 Hz and filtered by a 50 Hz low-pass filter, stored on 
magnetic media, and analyzed on a Dell Dimension XPS 
P90 computer (Dell Computer Corp., Austin, Tex.). 
Myocardial and lung biopsies. Generous 1.5 to 2 gm 
peripheral lung tissue samples were taken from the right 
upper lung lobe of all animals in both the CTL and MCTP 
groups after median sternotomy and anterior pericardiot- 
omy and analyzed with the use of light microscopy. 
Hematoxylin and eosin-stained sections were used to 
assess the pulmonary parenchyma and vasculature in all 
biopsy samples. 
Fourier analysis. Calculation of the impedance spec- 
trum of the pulmonary circulation from the collected raw 
data was done with Fourier analysis. Fourier analysis is 
based on the principle that all periodic waveforms may be 
broken down into a series of pure sine waves or harmon- 
ics. 5 Harmonics exist at frequencies that are multiples of 
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the frequency of the original waveform (the "fundamental 
frequency") and are described in terms of an amplitude 
and phase. Each harmonic represents an oscillatory com- 
ponent of the original waveform at its respective fre- 
quency. The net effect of Fourier analysis is to transform 
a waveform from the time domain, that is, wherein the 
waveform is described as a function of time, to the 
frequency domain, wherein it is described as a function of 
frequency. 
The pulsatile waveforms of the pulmonary artery pres- 
sure and flow can be treated as periodic waveforms 
possessing a fundamental frequency (that is, the heart 
rate). At each individual harmonic, division of the pres- 
sure amplitude by the flow amplitude allows one to obtain 
the oscillatory counterpart of resistance, impedance, at 
that respective harmonic. The array of individually calcu- 
lated impedance values from every harmonic represents 
the impedance spectrum. Input resistance is the imped- 
ance calculated at the zeroth harmonic and is a measure 
of resistance to mean pulmonary blood flow. Characteris- 
tic impedance is estimated as the mean impedance be- 
tween 2 and 12 Hz and is a measure of resistance to 
pulsatile blood flow. In theoretic terms, characteristic 
impedance is an index of the overall distensibility or 
stiffness of the pulmonary vascular bed. 
The product of the impedance amplitude, the square of 
the flow amplitude, and the cosine of the impedance 
phase angle for each individual harmonic give the individ- 
ual power at that particular harmonic. These products 
across all harmonics constitute the power spectrum, which 
represents the amount of energy, or hydraulic power, 
produced by the right ventricle to maintain pulmonary 
blood flow and are expressed as follows: 
Power = i~ Q2Zcos(dpz) 
where Q represents he flow amplitude, Z represents he 
impedance amplitude, and + represents the impedance 
phase angle. Hydraulic power can be divided into two 
components: teady power and oscillatory power. Steady 
power is the power obtained at the zeroth harmonic and 
represents lhe energy required to move blood forward at 
a steady state. Oscillatory power is taken from the remain- 
der of the power spectrum exclusive of the zeroth har- 
monic and reflects the energy that is wasted in oscillatory 
accelerations of blood and that eventually disseminates 
into vessel walls. 
Transpulmonary efficiency was defined as the ratio of 
mean pulmonary blood flow divided by right ventricular 
hydraulic power. Pulmonary vascular esistance was cal- 
culated by the standard formula applying mean pulmo- 
nary artery pressure, left atrial pressure, and cardiac 
output. 
Humane animal care. All animals received humane 
care in compliance with the "Princii~les of Laboratory 
Animal Care" formulated by the National Society for 
Medical Research and the "Guide for the Care and Use of 
Laboratory Animals" prepared by the Institute of Labo- 
ratory Animal Resources and published by the National 
Institutes of Health (NIH Publication No. 86-23, revised 
1985). The experiments were approved by the Duke 
University Institutional Animal Care and Use Committee 
(DUIACUC Assigned Registry No. A450-94-9). 
Statistical analysis. Statistical analysis was performed 
on a Dell personal computer with commercially available 
software (SigmaStat, Jandel Corporation, San Rafael, 
Calif.). Data taken before and after injection of monocro- 
taline pyrrole within the MCTP group were analyzed with 
standard two-tailed paired Student's t tests. To test for 
significant changes in the various parameters of pulmo- 
nary vascular impedance after NO administration within 
the MCTP group, a one-way analysis of variance for 
repeated measurements was used. Follow-up comparison 
between hemodynamic parameters atindividual evels of 
NO was done with paired Student's t tests. Unpaired 
Student's t tests were used to analyze data between the 
CTL and MCTP groups. The results are expressed as 
mean plus or minus the standard error of the mean. A 
difference was considered statistically significant at p < 
0.05. 
Results 
There were no significant differences in either the 
body weights or baseline hemodynamic parameters 
between the CTL and MCTP groups. In addition, 
there was no significant change in the body weights 
of animals in the MCTP group 6 weeks after mono- 
crotaline pyrrole injection compared with before 
injection. 
Hemodynamic changes. Significant increases in 
the mean right ventricular pressure and mean pul- 
monary artery pressure were observed in the MCTP 
group 6 weeks after monocrotaline pyrrole injection 
(13.08 + 0.57 mm Hg and 20.1 _+ 1.10 mm Hg, 
respectively, p < 0.001) compared with baseline 
measurements (8.25 _+ 0.49 mm Hg and 9.71 _+ 0.62 
mm Hg, respectively), whereas no significant 
changes were observed in heart rate (96 _+ 4 beats/ 
min vs 85 _+ 5 beats/min) or central venous pressure 
(3.75 + 0.45 mm Hg vs 3.13 + 0.35 mm Hg).  In 
addition, there was a significant increase in the 
pulmonary vascular esistance in the MCTP group 6 
weeks after monocrotaline pyrrole injection com- 
pared with values in the CTL group (951 ± 129 
dyne. sec. cm -5 vs 461 _+ 37 dyne- sec- cm -5, p = 
0.002). A significant increase in the pulmonary 
capillary wedge pressure was also observed in the 
MCTP group 6 weeks after monocrotaline pyrrole 
injection compared with before injection (6.25 ± 
0.75 mm Hg vs 4.13 ± 0.40 mm Hg, p = 0.025). 
Changes in pulmonary vascular mechanics after 
monocrotaline pyrrole injection. Six weeks after the 
monocrotaline pyrrole injection, there was a de- 
crease in the pulmonary blood flow from 1384 ± 87 
ml/min in the CTL group to 1236 ± 92 ml/min in the 
MCTP group, although this difference was not sta- 
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Table I. Effect of monocrotaline pyrrole-induced chronic pulmonary hypertension on pulmonary 
vascular mechanics 
Qpa RIN Z o HP SP OP EFF 
(ml/min) (dyne. sec . cm -s) (dyne. sec . cm -s) (roW) (roW) %SP (mW) %OP (ml/min/mW) 
CTL  (n = 8) 1384 (87) 685 (59) 223 (21) 50 (3.0) 35 (2.5) 71 (2.7) t5 (1.5) 29 (2.7) 36.2 (2.3) 
MCTP (n = 8) 1236 (92) 1325 (137)* 227 (32) 68 (7.6)? 54 (5.3); 80 (1.9)§ 14 (2.6) 20 (1.9)§ 24.9 (2.5)11 
The standard error of the mean is given in parentheses. Qpo, Pulmonary blood flow; R/N, input resistance; Zo, characteristic impedance; HP, hydraulic power; 
SP, steady power; %SP, percentage of hydraulic power comprising steady power; OP, oscillatory power; %OP, percentage of hydraulic power comprising 
oscillatory power; EFF, transpulmonary efficiency. 
*p < 0.001 versus CTL. 
tp - 0.035 versus CTL. 
~p - 0.005 versus CTL. 
§p = 0.013 versus CTL. 
lie = 0.00l versus CTL. 
tistically significant. There were significant increases 
in both input resistance and right ventricular hy- 
draulic power in the MCTP group compared with 
values in the CTL group. Steady power was also 
significantly increased, whereas transpulmonary ef- 
ficiency was significantly decreased in the MCTP 
group compared with that in the CTL group. No 
significant differences were observed in the charac- 
teristic impedance or oscillatory power between the 
two groups 6 weeks after the injection. The changes 
in pulmonary vascular mechanics after monocrotal- 
ine pyrrole injection are summarized in Table I. 
Effect of inhaled NO on pulmonary vascular 
mechanics. After NO administration i the MCTP 
group, the mean pulmonary artery pressure de- 
creased significantly at both 40 ppm and 80 ppm 
compared with the baseline value, although no 
further significant decrease was observed in the 
mean pulmonary artery pressure at 80 ppm of NO 
compared with that at 40 ppm (Fig. 1). The pulmo- 
nary vascular resistance was also significantly de- 
creased after NO administration compared with the 
baseline value (Fig. 2). These levels after NO ad- 
ministration were not significantly different com- 
pared with preinjection levels. 
NO led to significant increases in both mean pul- 
monary blood flow and transpulmonary efficiency in 
the MCTP group at 40 ppm and 80 ppm compared 
with values at 0 ppm. Left atrial pressure and left 
ventricular filling were also significantly increased at 80 
ppm NO compared with values at 0 ppm. In addition, 
there were significant decreases in the input resistance 
at 40 ppm and 80 ppm compared with the value at 0 
ppm. No significant differences in the right ventricular 
hydraulic power, steady power, or oscillatory power 
were observed after NO administration. The effects of 
inhaled NO on pulmonary vascular mechanics are 
summarized in Table II. 
Gross and microscopic lung tissue analysis. 
Gross examination of the lungs in the MCTP group 
revealed no obvious abnormalities compared with 
CTL-group lungs. Microscopic examination of he- 
matoxylin and eosin-stained lung sections in the 
CTL group revealed normal thin-walled pulmonary 
arterioles and alveolar septae. Lung sections from 
all experimental nimals in the MCTP group dem- 
onstrated thickening of the small and medium pup 
monary arterioles with smooth muscle hypertrophy 
within the vessel walls in every specimen (Fig. 3). 
There was also increased cellularity and widening of 
the alveolar septae. The majority of the small pul- 
monary arterioles observed were nearly obliterated 
because of increased amounts of stromal tissue and 
fibrous connective tissue surrounding these vessels. 
Discussion 
NO is an endogenously occurring endothelium- 
derived relaxing factor produced from L-arginine by 
endothelial NO synthetase. 6' 7Whether produced by 
the endothelial cells or after exogenous administra- 
tion by inhalation, NO rapidly diffuses directly into 
the pulmonary vascular smooth muscle cells where it 
leads to increases in the concentration of guanylate 
cyclase, s The rise in the level of guanylate cyclase 
results in relaxation and vasodilation of the pulmo- 
nary vascular smooth muscle. Once NO diffuses 
through the smooth muscle cell into the vessel 
lumen, however, it reacts quickly with hemoglobin. 
Hemoglobin inactivates NO and prevents it from 
causing any systemic vasodilation. In this way, the 
vasodilating actions of inhaled NO are focused on 
the pulmonary circulation with virtually no systemic 
effects. 9 These properties offer a significant advan- 
tage for NO as a selective pulmonary vasodilator. 
Clinically, NO has successfully improved pulmo- 
nary hemodynamics in primary pulmonary hyper- 
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Fig. 1. Bat graph displaying the significant increase in the 
mean pulmonary artery pressure (mPAP) in the monocro- 
taline pyrrole-treated group 6 weeks after injection com- 
pared with before injection and the effects of NO admin- 
istration. Six weeks after monocrotaline pyrrole injection, 
significant decreases in the mean pulmonary artery pres- 
sure were observed after NO administration, although 
these posttreatment levels continued to be significantly 
elevated compared with those before injection: *p < 0.001 
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Fig. 2. Bar graph displaying the significant increase in the 
pulmonary vascular esistance (PVR) in the monocrotal- 
ine pyrrole-treated group 6 weeks after injection com- 
pared with before injection and the effects of NO admin- 
istration. Six weeks after injection of monocrotaline 
pyrrole, significant decreases in the pulmonary vascular 
resistance were observed after NO administration to 
levels that were not significantly different from preinjec- 
tion values. *p = 0.002 versus preinjection; *p < 0.001 
versus postinjection, 0 ppm NO. 
tension 1° and in pulmonary hypertension caused by 
congenital heart defects, ~1 mitral valve disease, ~2 
and adult respiratory distress yndromel ~3 as well as 
after cardiac operations. 14NO has also been used in 
the treatment of chronic puhnonary hypertension i  
patients with congestive heart failure 15 and in the 
evaluation and identification of reversible pulmo- 
nary hypertension i  patients awaiting cardiac trans- 
plantationo 16
In the experimental setting, NO has been re- 
ported to lower pulmonary artery pressure, albeit in 
the setting of acute pulmonary hypertension, in 
animal models of acute hypoxia, ~7 endotoxin 
shock, 18 and acute lung injury. 19 Few reports, how- 
ever, describe the experimental use of NO for 
improving pulmonary hemodynamics in the setting 
of chronic pulmonary hypertension. 
This report brings several novel approaches to 
basic investigation of the effects of NO on pulmo- 
nary hemodynamics in the setting of chronic pul- 
monary hypertension. First, a recently established 
canine model of monocrotaline pyrrole-induced 
chronic pulmonary hypertension was used. Several 
other models of pulmonary hypertension exist as 
potential means to evaluate the different pharmaco- 
logic options for improving pulmonary hemodynam- 
ics in the setting of chronically elevated pulmonary 
vascular pressure. These models use a variety of 
methods to induce pulmonary hypertension, includ- 
ing embolization, 2° banding Of the pulmonary ar- 
tery, 2~ and pulmonary venous constriction. 22 Al- 
though each previous model resulted in a significant 
rise in pulmonary vascular pressure, the pressure 
increases were accomplished in an acute manner 
and do not mimic the chronic nature of chronic 
pulmonary hypertension. In addition, the parenchy- 
real changes een in association with primary pul- 
monary hypertension were not reported in any 
previous model. As a result, these models do not 
adequately represent the clinical picture of chronic 
pulmonary hypertension. 
Monocrotaline pyrro!e-induced chronic pulmo- 
nary hypertension is characterized by a proliferative 
vasculitis. 23 After intravenous injection, the parent 
compound, monocrotaline, undergoes hepatic me- 
tabolism by the cytochrome P450 monooxygenase 
system to form a reactive metabolite, monocrotaline 
pyrrole, which in turn circulates to the pulmonary 
vascular bed where lung injury is induced. The initial 
endothelial injury leads to increased capillary per- 
meability, which results in interstitial and alveolar 
edemaY Remodeling of the pulmonary vascular 
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Fig. 3. Photomicrograph of a hematoxylin and eosin-stained specimen of lung tissue taken from an 
experimental nimal 6 weeks after monocrotaline pyrrole injection illustrating plexiform changes in the 
arterioles. There is increased connective tissue, smooth muscle proliferation, and adventitia surrounding 
the medium-sized pulmonary arteriole. 
Table II. Effect of inhaled NO on pulmonary vascular mechanics in etting of monocrotaline pyrrole-induced 
chronic pulmonary hypertension 
PaN Zo 
NO Qpa (dyne" (dyne. HP SP OP EFF LAP LFV 
(pprn) (ml/rnin) sec. cm -5) sec" cm -#) (roW) (roW) %SP (roW) %OP (ml/min/mW) (turn Pig) (ml) 
MCTP 0 1236 (92) 1325 (137) 227 (32) 68 (7.6) 54 (5.3) 80 (1.9) 14 (2.6) 20 (1.9) 24.9 (2.5) 5.7 (0.6) 46 (4.4) 
(n = 8) 
MCTP 40 1455 (140)* 976(128)t 260 (23) 70 (9.6) 55 (7.6) 79(1.0) 15 (2.1) 21 (1.0) 33.4 (3.5)$ 7.02 (0.4) 49 (5) 
(n = 8) 
MCTP 80 1469 (115)* 945 (85)t 250 (39) 72 (8.8) 56 (7.1) 77 (1.6) 16 (2.0) 23 (1.6) 33.2 (3.2)5 7.55 (0.4)§ 51 (4.9)11 
(n = 8) 
The standard error of the mean is given in parentheses. Qpo, Pulmonary blood flow; R/N, input resistance; Z~o characteristic impedance; HP, hydraulic power; 
SP, steady power; %SP, percentage of hydraulic power comprising steady power; OP, oscillatory power; %OP, percentage of hydraulic power comprising 
oscillatory power; EFF, transpulmonary efficiency; LAP, left atrial pressure; LVV, left ventricular volume. 
*p = 0.021 versus MCTP, 0 ppm NO. 
tp = 0.003 versus MCTP, 0 ppm NO. 
:[:p < 0.001 versus MCTP, 0 ppm NO. 
§p - 0.014 versus MCI'P, 0 ppm NO. 
lip = 0.030 versus MCTP, 0 ppm NO. 
bed at the level of the medium and small pulmonary 
arterioles, which occurs in response to this injury, is 
responsible for the rise in hemodynamic pressures. 
Light microscopy examination of lung biopsy 
specimens from animals treated with monocrotaline 
pyrrole revealed endothelial cell degeneration and 
hyperplasia nd medial smooth muscle hypertrophy 
with subsequent medial thickening affecting both 
the small and medium arterioles. These findings 
closely mimic the changes observed in a pathologic 
type of primary pulmonary hypertension known as 
plexogenic pulmonary arteriopathy. 24 Thus the 
model of pulmonary hypertension described in this 
report accurately reflects the clinical picture of 
primary pulmonary hypertension not only because it
is chronic, but also, more important, because the 
parenchymal changes that occur as a result of mono- 
crotaline pyrrole injection are similar to the micro- 
scopic findings observed clinically in chronic pulmo- 
nary hypertension. 
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A possible criticism of this model is that the 
absolute level of pulmonary hypertension observed 
after monocrotaline pyrrole injection is not reflec- 
tive of the clinical picture of chronic pulmonary 
hypertension. It is important to note, however, that 
the pulmonary vascular pressures observed in the 
canines before drug injection in these experiments 
were significantly lower than normal evels found in 
a human being. Although a twofold increase in the 
mean puhnonary artery pressure and pulmonary 
vascular esistance was achieved, the resultant levels 
are, admittedly, still lower than those usually seen 
clinically. ][t is unclear from the data presented in 
this report whether any further significant increase 
in pulmonary hemodynamic values would occur at 
more than 6 weeks after monocrotaline pyrrole 
injection, and this will require further study. A 
potential way to refine this model and possibly 
achieve a higher degree of pulmonary hypertension 
would be to perform numerous injections of mono- 
crotaline pyrrole at regularly spaced intervals. Mul- 
tiple injections in the same animal would theoreti- 
cally cause repeated injury to the pulmonary 
vascular bed and produce greater scarring of the 
pulmonary vasculature, resulting in higher pulmo- 
nary pressures. 
Admittedly, this model does not precisely reflect 
the exact clinical picture of chronic pulmonary hy- 
pertension:, although the picture it does provide 
succeeds where previous models have failed. 
Clearly, no single experimental model could possibly 
replicate the entire pattern of chronic pulmonary 
hypertension. Therefore the choice of any one es- 
tablished or new animal model should be based on 
the need to answer a particular question without 
attempting to produce an exact replica of any one 
single disease process. 
This report is also unique in that Fourier analysis 
was used to calculate pulmonary vascular imped- 
ance and right ventricular hydraulic power. The 
pulmonary vascular bed represents a highly compli- 
ant, low-resistance conduit that is subject o pulsa- 
tile blood flow. Traditional measurements of steady- 
state hemodynamic parameters, such as mean 
pulmonary artery pressure, pulmonary vascular e- 
sistance, and mean pulmonary artery blood flow, do 
not fully characterize the nature of the pulmonary 
circulation in terms of its physical state. The appli- 
cation of Fourier analysis to the parameters of 
pulmonary artery pressure and blood flow in this 
report separates these measurements into their re- 
spective steady-state and pulsatile components, re- 
suits in a complete and quantitative description of 
the pulmonary vascular bed in the form of vascular 
impedance, gives information regarding the physical 
state of the pulmonary vasculature, and thoroughly 
assesses the effects of NO on these components. The 
interactions of the right ventricle and its afterload 
can also be assessed with Fourier analysis to pre- 
cisely define the external oad against which the 
right ventricle must pump to move blood forward 
through the pulmonary circulation. This analysis 
allows for determination of right ventricular hydrau- 
lic power and divides this power into its components 
of steady power and oscillatory power. The use of 
Fourier analysis to assess biologic systems has been 
previously investigated and validated for the pulmo- 
nary vascular systems in both canine and human 
models. 25 
The smooth muscle hypertrophy and perivascular 
connective tissue proliferation observed in the small 
and medium arterioles of all experimental nimals 
treated with monocrotaline pyrrole may account for 
the significant increases in pulmonary vascular im- 
pedance and right ventricular hydraulic power and 
the significant decreases in transpulmonary effi- 
ciency. These findings suggest hat vascular injury 
caused by monocrotaline pyrrole leads to a situation 
in which the pulmonary circulation does not allow 
blood to flow as easily or efficiently. On several 
occasions, the increased vascular cellular hyperpla- 
sia observed in the pulmonary specimens was so 
pronounced that the vessel umen was nearly, if not 
completely, occluded. These microscopic hanges 
led to decreased vascular compliance and increased 
right ventricular afterload. Significantly greater 
amounts of energy expenditure were required by the 
right ventricle to maintain the same degree of 
pulmonary blood flow. This forward blood flow was 
maintained at a steady state, but was achieved at a 
significantly lower level of efficiency. 
In addition to the significant improvements in
conventional steady-state flow hemodynamics, NO 
led to only slight increases in right ventricular 
hydraulic power and insignificant changes in both 
the steady power and oscillatory power. Thus, in this 
model of pulmonary hypertension, the beneficial 
effects of NO appear to be related to its well- 
established ability to selectively dilate the pulmo- 
nary circulation. By exclusively reducing pulmonary 
impedance and hence the external load against 
which the right ventricle must pump, NO resulted in 
significant increases in pulmonary blood flow and 
transpulmonary efficiency, all without acting directly 
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on the myocardium as a positive inotrope or increas- 
ing the energy expenditure of the right ventricle. 
These improvements in pulmonary blood flow char- 
acteristics, in turn, led to the significant increases in 
left ventricular filling pressures. 
The significant increases that occurred in left 
atrial pressure and left ventricular volume after NO 
administration were interesting and surprising find- 
ings in this report. These observations are, however, 
consistent with those in previous investigations in
which an increase in the pulmonary capillary wedge 
pressure was associated with a decrease in pulmo- 
nary vascular esistance during infusion of adeno- 
sine in patients with heart failure. 26 Although the 
exact mechanism for this observation remains un- 
clear, it appears that left ventricular preload in- 
creased as a result of the significantly greater 
amount of blood passing through the pulmonary 
circulation to the left side of the heart. 
The improvements in pulmonary vascular imped- 
ance, transpulmonary efficiency, and left ventricular 
filling after NO administration suggest that the 
pulmonary circulation is responsive to pharmaco- 
logic therapy after monocrotaline pyrrole-induced 
pulmonary vascular injury and that irreversible dam- 
age has not occurred. Interestingly, in a previous 
study examining the role of NO in the setting of 
monocrotaline-induced chronic pulmonary hyper- 
tension, Mathew and associates 27demonstrated that 
by 2 weeks after monocrotaline injection NO-re- 
lated relaxation was significantly impaired compared 
with baseline data in a rat model. In that investiga- 
tion, exposure of pulmonary artery rings to both 
L-arginine and acetylcholine failed to result in any 
vasorelaxation. 
The rat model of monocrotaline-induced pulmo- 
nary hypertension has been extensively described in 
the literature. The main disadvantage to the use of 
rats is the small body size, which makes it technically 
difficult to accurately assess pulmonary hemody- 
namics and ventricular volumes in a chronic pulmo- 
nary hypertension model. More important, however, 
the pulmonary circulation of a rat is quite different 
from that of a human being with respect o vessel 
ultrastructure, remodeling patterns, and pathologic 
reactions to injury, which makes it a poor animal 
model for the study of human chronic pulmonary 
hypertension, a8 
The findings of Mathew and associates 27suggest 
that irreversible pulmonary vascular injury occurred 
after monocrotaline treatment and that no signifi- 
cant hemodynamic response to NO should be ex- 
pected, which apparently contradicts the findings 
reported in this study. It is important to note, 
however, that NO-mediated vasorelaxation can oc- 
cur through both endothelium-dependent, via en- 
dogenous production, and endothelium-indepen- 
dent mechanisms. In the study by Mathew and 
associates, 27 vasorelaxation of pulmonary vascular 
rings was attempted with acetylcholine. Acetylcho- 
line, in addition to L-arginine as previously men- 
tioned, mediates vasodilation by an endothelium- 
dependent pathway, 29 and failure to observe any 
pulmonary vasorelaxation i  this particular circum- 
stance would certainly be consistent with the docu- 
mented mechanisms of monocrotaline pyrrole-in- 
duced pulmonary endothelial injury. 
In the present study, NO was directly adminis- 
tered into the alveolar air spaces. When given in this 
manner, NO diffuses across the alveolar-capillary 
membrane to increase guanylate cyclase levels in 
vascular smooth muscle, causing pulmonary vasodi- 
lation, and directly bypasses the endothelial cells. 
Thus the improvement in pulmonary vascular im- 
pedance observed in this report occurred through an 
endothelium-independent mechanism, and in the 
setting of monocrotaline pyrrole-induced pulmo- 
nary endothelial injury it appears that mechanisms 
of pulmonary vasodilation via vascular smooth mus- 
cle cells are at least partially intact. 
Because of the previously well-described injury to 
pulmonary vascular endothelial cells and the subse- 
quent changes that occur in the vascular smooth 
muscle as a result of monocrotaline pyrrole injec- 
tion, it was initially unclear whether the endotheli- 
urn-dependent and the endothelium-independent 
mechanisms of NO-mediated vasorelaxation would 
be altered. Consequently, it was decided to use a 
relatively high concentration of NO in an attempt to 
potentially demonstrate a significant hemodynamic 
response. Although lower concentrations of NO, 
such as 10 ppm or 20 ppm, may be equally effective 
in reducing vascular impedance as the concentra- 
tions used in this report, such a conclusion is not 
possible on the basis of the data presented in this 
study. Future studies should examine whether 10 
ppm or 20 ppm NO would be effective in improving 
pulmonary vascular impedance and efficiency in the 
setting of canine chronic pulmonary hypertension 
caused by monocrotaline pyrrole. 
It is doubtful that any improvements in pulmo- 
nary hemodynamics in this model could be achieved 
by simply increasing the fraction of inspired oxygen 
while simply ventilating the lungs of animals previ- 
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ously given an injection of monocrotaline pyrrole, 
because the fraction of inspired oxygen was kept at 
least at 60% at the time of instrumentation. This was 
done to maximally stabilize the condition of the 
animals during the extremely invasive surgical pro- 
cedures required for placement of all devices used 
for data collection in these studies. 
In summary, an adult canine model of chronic 
pulmonary hypertension provides a useful and reliable 
means by which to evaluate the effects of inhaled NO 
on pulmonary hemodynamics in the setting of chron- 
ically elevated pulmonary vascular pressure. The well- 
known clinical effects of NO in improving pulmonary 
hemodynamics were observed and, in the setting of 
monocrotaline pyrrole-induced chronic pulmonary 
hypertension, were also associated with significant 
improvements in transpulmonary efficiency and left 
ventricular filling. These data suggest hat NO may be 
a potentially useful means for significantly improving 
pulmonary vascular impedance and efficiency in the 
setting of chronic pulmonary hypertension. 
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